Contents

Search

ferumoxytol (Feraheme, ferrosoferric oxide)

Indications: - iron replacement in anemia of chronic kidney disease & iron-deficiency anemia - useful as MRI contrast agent [3] Dosage: - intravenous iron replacement - given by IV push in just 2 doses of 510 mg 3-8 days apart Injection: 30 mg/mL (elemental iron) solution for injection in 17 mL vials containing 510 mg of elemental iron. Adverse effects: - hypotension, dizziness (2%) - anaphylaxis (boxed warning) [4] Mechanism of action: - superparamagnetic form of iron oxide, with a carbohydrate shell - contains iron nanoparticle

Interactions

drug adverse effects of contrast agents

General

hematologic agent contrast agent

Database Correlations

PUBCHEM cid=14789

References

  1. Prescriber's Letter 16(9): 2009 New Drug: Feraheme (Ferumoxytol) Detail-Document#: 250913 (subscription needed) http://www.prescribersletter.com
  2. Prescriber's Letter 17(2): 2010 New Drugs Approved by the FDA in 2009 Detail-Document#: 260213 (subscription needed) http://www.prescribersletter.com
  3. Klenk C et al Ionising radiation-free whole-body MRI versus 38F-fluorodeoxy- glucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. The Lancet Oncology, Early Online Publication, 19 February 2014 PMID: 24559803 http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970021-X/abstract
  4. FDA Drug Safety Communication: March 30, 2015 FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm